Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcuminoids for Prevention of Contrast-Induced AKI in CKD
NCT04890704Phase 1Completed
- Sponsor
- Vajira Hospital
- Start
- Oct 2018
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in contrast-induced acute kidney injury (CI-AKI) comparing Curcuminoids with Placebo (2 arms). Primary endpoint: Incidence of Contrast-Induced Acute Kidney Injury at 48 hours. Started Oct 2018; status: completed.
02
Drugs
curcuminoids
03
Conditions
contrast-induced acute kidney injury (CI-AKI)
Beyond the preview
Go deeper on NCT04890704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890704.